Korean J Lab Med.  2007 Feb;27(1):22-27. 10.3343/kjlm.2007.27.1.22.

Usefulness of NMP22 BladderChek for the Diagnosis and Monitoring of Bladder Cancer

• Seo S
• Cho S
• Hong K
• Shim B
• Kwon S

• KMID: 1121655
• DOI: http://doi.org/10.3343/kjlm.2007.27.1.22

Abstract

BACKGROUND: As bladder cancer is a superficial tumor with frequent recurrences, early detection and confirmation of recurrence are important. We evaluated the usefulness of NMP22 BladderChek (NMP22BC) for the diagnosis and monitoring of bladder cancer. METHODS: From July to December 2004, we enrolled in the study 670 patients who visited the urology clinic in Ewha Womans University, Dongdaemun Hospital with hematuria or dysuria and were tested with NMP22BC. We also performed the NMP22BC and BTA stat tests simultaneously in 21 patients and interference test in 10 patients. RESULTS: NMP22BC tests were negative in 97% of the patients who had been cured of bladder cancer and were positive in 95% of the patients with recurred bladder cancer. The diagnostic sensitivity, specificity, positive and negative predictive value, and efficiency were 95.0%, 91.5%, 25.7%, 99.8%, and 91.6%, respectively, with 8.5% false positive and 5% false negative rates. Fifty-five patients showed false positive in the NMP22BC test, the main cause of which was the presence of WBCs in urine. There was a good agreement between the NMP22BC and BTA stat tests (kappa agreement value, 0.5; P=0.008). According to the interference test, two patients with more than 3+ in leukocyte esterase results showed false positive in the NMP22BC test. CONCLUSIONS: NMP22BC test was simple to perform, rapid to produce the results, and useful in diagnosing a bladder cancer recurrence; the test shows a high efficiency with a high sensitivity, specificity, negative predictive value, and low false negative rate.

Keyword

Bladder cancer; NMP22 BladderChek; Point-of-care test

MeSH Terms

Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Monitoring, Physiologic
Nuclear Matrix-Associated Proteins/*urine
Nuclear Proteins/*urine
Reagent Kits, Diagnostic
Urinary Bladder Neoplasms/*diagnosis

Reference

References

1. Shin HR, Jung KW, Won YJ, Park JG. 2002 annual report of the Korea central cancer registry: based on registered data from 139 Hospitals. Cancer Res Treat. 2004; 36:103–14.

2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997; 33:1075–107.

3. Tomera KM. NMP22 BladderCheck Test: point of care technology with life- and money-saving potential. Expet Rev Mol Diagn. 2004; 4:783–94.

4. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986; 135:920–2.

5. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130:1083–6.

6. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol. 1993; 150:60–4.

7. Walsh PC, Retik AB, editors. Campbell's urology. 8th ed.Philadelphia: Saunders;2002. :2750.

8. National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf.v.1.2007.

9. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998; 52:398–402.

10. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006; 295:299–305.

11. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology. 2005; 66(S1):):S35–63.

12. Moonen PM, Kiemeney LA, Witjes JA. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol. 2005; 48:951–6.

13. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 Bladder-Chek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol. 2006; 36:172–5.

14. Miyanaga N, Akaza H, Tsukamoto S, Shimazui T, Ohtani M, Ishikawa S, et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol. 2003; 8:369–73.

15. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999; 162:53–7.

16. Tomera K, Clark WR, Singsaas MW, Strawbridge LR. Results of screening high risk patients for urothelial cancers with a new office test-NMP22 BladderCheck. J Urol. 2003; 169(S):):S226–7.

17. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 2001; 166:75–8.

18. Chen YT, Hayden CL, Marchand KJ, Makuch RW. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol. 1997; 158:1899–901.

19. Gutierrez C, Palou J, Bujons A, Iglesias JC, Juaneda B, Segarra J, et al. The detection of nuclear matrix protein 22 in the follow up of patients after endovesical treatment with BCG. Eur Urol. 2004; S3:97.

20. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta. 2004; 340:57–65.

21. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int. 2003; 92:911–4.

22. Kim YH, Cho WJ, Hong KS, Koo HS, Shim BS, Kwon SW. Evaluation of the usefulness of immediate-cytospin Wright-stained urine cytology in the screening and monitoring of bladder cancer. Korean J Lab Med. 2003; 23:164–9.

23. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. Urol Oncol. 2006; 24:338–43.

24. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology. 2002; 60:593–7.